The Wall Street Journal

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030

Investment includes plans for a new manufacturing center focused on chronic diseases

AstraZeneca’s planned investment come as President Trump threatens to impose tariffs on pharmaceuticals made abroad.
AstraZeneca’s planned investment come as President Trump threatens to impose tariffs on pharmaceuticals made abroad. Photo: Graeme Sloan/Bloomberg News

AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, marking the latest drugmaker to commit to American manufacturing as looming tariffs threaten to raise costs across the industry.

The biopharmaceutical company said Monday that the investment includes plans for a new manufacturing center focused on chronic diseases. The multibillion-dollar facility would support the company’s weight-management and metabolic portfolio, including oral GLP-1s.

WSJ Logo
Bosses Should Never Speak First, or Even Second, in a MeetingExternal link

Bosses Should Never Speak First, or Even Second, in a Meeting